AbbVie Inc.
In the published model solve dated 2026-Q2, anchored at $256.00, AbbVie Inc. (ABBV) is priced for +14.0% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Two drugs launched to replace one now carry 43% of revenue between them, and the 10-K reports that ⟦"Net revenues for Skyrizi increased 50% in 2025 primarily driven by continued strong market share uptake as well as market growth across all indications"⟧ on a constant-currency basis. • The old franchise is still unwinding underneath that, with the Q1 FY2026 10-Q reporting Humira net revenues down 40% in the March 2026 quarter on direct biosimilar competition, which is what a patent cliff looks
Is ABBV overvalued? See what's priced in →
3,989 institutional managers reported holding ABBV in 13F filings for the quarter ended 2026-03-31. Together they hold about 70% of the company; the top 10 hold 35%. 128 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 23.4M shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (4.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ABBV's share count is about flat over the past five years ($7.78B of repurchases, offset by issuance). It pays a dividend, and has paid one every year in our records (13 and counting), raised 12 years straight; the current rate is $6.65 a share annually. Cash returned over the past three years: $31.02B in dividends and $4.19B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at ABBV over the trailing three years. Absence is a fact about the company, not a signal. 26 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ABBV's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-08 | +6.3% | -0.5% |
| 2023-11-07 | -4.3% | +14.2% |
| 2024-02-21 | -1.3% | -4.2% |
| 2024-05-04 | -4.6% | +2.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ABBV's latest 8-K filings: 2026-08-18 (items 8.01, 9.01); 2026-08-05 (items 8.01, 9.01); 2026-07-31 (items 2.02, 9.01); 2026-07-06 (items 2.02, 9.01); 2026-06-22 (items 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.